Skip to main content

Table 3 Cohort characteristics

From: Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study

Characteristic Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 All sites
Total sample size 149 149 147 149 102 150 846
Follow up time, months 12 36 12 12 12 36 ---
Median age at ART initiation, years [IQR] 35 [30–40] 35 [30–43] 34 [29–40] 33 [29–42] 35 [31–41] 37 [31–46] 35 [30–42]
Sex, % female 63 52 68 66 45 58 60
Median CD4 at ART initiation, cells/μL [IQR]a 149 [97–211] 127 [67–206] 136 [84–199] 150 [77–237] 140 [74–273] 160 [106–209] 145 [86–212]
Regimen at ART initiation, % of patients        
TDF-containing regimen 36 86 80 15 54 80 59
AZT-containing regimen 30 5 13 4 30 7 14
ABC-containing regimen 0 5 0 76 0 0 14
d4T-containing regimen 34 5 7 5 16 13 13
  1. ART: antiretroviral therapy; ABC: abacavir; AZT: zidovudine; d4T: stavudine; IQR: interquartile range; TDF: tenofovir.
  2. a793 of 846 patients in the sample had a CD4 cell count at initiation.